July 8, 2026 - 21:54

Oracle Corporation (NYSE:ORCL) is getting attention as a potential bargain in the technology sector, especially for investors focused on the artificial intelligence buildout. On July 1, the research firm Blair added the stock to its analyst conviction list. The firm believes Oracle has become a key player in the AI infrastructure race, largely because of major commitments from hyperscale cloud providers. These deals are giving the company strong revenue visibility for the foreseeable future.
The stock has taken a hit recently, which some analysts see as an overreaction. Despite the dip, Oracle's cloud business is expanding rapidly. The company is investing heavily in data centers and GPU clusters to meet the growing demand for AI computing power. This positions Oracle to benefit from the long-term trend of companies moving their workloads to the cloud and building out AI models.
For investors looking for a beaten-down stock with a clear catalyst, Oracle offers a mix of value and growth potential. The company's established software base provides a steady stream of cash, while the new AI-related contracts could drive significant upside. While the stock is not without risk, the current price may represent a good entry point for those who believe the AI buildout is still in its early stages.
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...
September 27, 2026 - 08:32
New Biochip Enables Real-Time Tracking of Parkinson's Treatment ResponseResearchers have created a biochip technology that allows for real-time monitoring of how Parkinson`s disease patients respond to treatment. The development comes from a team working on advanced...